Plains GP Holdings LP

In a Stage 2 advancing regime with higher highs & higher lows intact, the stock held a controlled pullback into its rising 9- and 20-day EMAs, confirming structural support. Momentum remains constructive (RSI mid-60, moderate Options Score), and proximity to the 52-week high favors continuation. With medium- and short-term biases bullish, execution is favorable now via continuation participation near the EMA support zone.

• ↑Q2 2026 adj EBITDA of $738 M aligns with $2.88 B full-year target
• ↑2026 capex raised to $400–450 M for quick-hit growth projects
• ↓Stock appears ~9% overvalued versus $24.14 fair value estimate